<DOC>
	<DOCNO>NCT01061190</DOCNO>
	<brief_summary>The objective trial ass safety efficacy neuro- cardioprotective effect propranolol acute ischemic stroke . Furthermore , exploratory analysis cardiologic-electrophysiologic immunologic parameter perform .</brief_summary>
	<brief_title>Beta Blockers In Acute Ischemic Stroke</brief_title>
	<detailed_description>The main objective trial ass efficacy safety propranolol middle cerebral artery stroke patient . The primary hypothesis follow : Early administration propranolol reduces frequency cardiovascular and/or neurological complication include vascular death first 30 day acute ischemic stroke . Secondary hypothesis follow : Early administration propranolol improve neurological functional outcome patient acute ischemic stroke . Early administration propranolol reduce post-stroke immunodepression therefore lower rate pneumonia acute ischemic stroke , without increase frequency auto-aggressive , CNS antigen-specific T cell . Early administration propranolol influence alteration cardiologic , electrophysiologic phenomenon reaction autonomic dysregulation acute ischemic stroke . Early administration Propranolol reduce growth infarct determine MRI examination first 6 day .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Adrenergic beta-Antagonists</mesh_term>
	<mesh_term>Propranolol</mesh_term>
	<criteria>Symptom onset within 18 hour Acute ischemic MCAterritory stroke Patients suspect stroke MCAterritory ) NIHSS &gt; 3 b ) image evidence MCAinfarction Patients already receive betablockers Antiarrhythmic , antiinfectious , antiinflammatory immunosuppressive therapy Patients major heart disease , hypotension , bradycardia contraindication use Propranolol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Stroke</keyword>
</DOC>